Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2019 | 09-2019 | 06-2019 | 03-2019 | 12-2018 | |
| Sales | 8,899,000 | 9,385,000 | 7,809,000 | 7,661,000 | 8,197,000 |
| Cost of Goods | 3,248,000 | 3,245,000 | 2,637,000 | 2,733,000 | 2,904,000 |
| Gross Profit | 5,651,000 | 6,140,000 | 5,172,000 | 4,928,000 | 5,293,000 |
| Operating Expenses | 4,584,000 | 3,980,000 | 3,688,000 | 3,410,000 | 2,158,000 |
| Operating Income | 1,067,000 | 2,160,000 | 1,484,000 | 1,518,000 | 3,135,000 |
| Interest Expense | 179,000 | 245,000 | 237,000 | 224,000 | 182,000 |
| Other Income | 823,000 | 36,000 | 17,000 | 1,000 | -1,579,000 |
| Pre-tax Income | 1,711,000 | 1,951,000 | 1,264,000 | 1,295,000 | 1,374,000 |
| Income Tax | 194,000 | 235,000 | 214,000 | 310,000 | 74,000 |
| Net Income Continuous | 1,517,000 | 1,716,000 | 1,050,000 | 985,000 | 1,300,000 |
| Minority Interests | -218,000 | -164,000 | -86,000 | -155,000 | -85,000 |
| Net Income | $1,299,000 | $1,552,000 | $964,000 | $830,000 | $1,215,000 |
| EPS Basic Total Ops | 0.33 | 0.39 | 0.24 | 0.21 | 0.31 |
| EPS Basic Continuous Ops | 0.33 | 0.39 | 0.24 | 0.21 | 0.31 |
| EPS Diluted Total Ops | 0.32 | 0.39 | 0.24 | 0.21 | 0.31 |
| EPS Diluted Continuous Ops | 0.32 | 0.39 | 0.24 | 0.21 | 0.31 |
| EBITDA(a) | $1,890,000 | $2,709,000 | $2,277,000 | $2,702,000 | $2,243,000 |